Their taxes are extremely low this quarter. Why are they using such a low rate?
I just decided to buy another 10,000 shares. The bid was at .4219 and ask was at .422 There were 6 orders at the bid, in the 300-500 share range, trying to buy at .4219! Why would anyone try to buy at .0001 less than the ask. Obviously, I hit the ask without hesitation. Do you people buying not realize that the difference you are paying is only 4 cents total for a 400 share order? If 4 cents makes a difference in your life, then you better get a different life. If paying 4 cents more makes any difference in your trading, then you better stop trading. I see this all the time. I just can't believe how stupid retail traders are.
how stupid little retail short sellers and longs selling here are. People who loved a stock when its market cap was near a billion dollars now hate it and want out with the market cap around 60 million. Very little has changed with the drug and loads of potential lies ahead, yet little people think they know more than people with hundreds of millions of dollars at stake. It is no wonder that 80% of retail traders lose money. I'm now averaged in here at around 44 cents and I want to thank all of you for this gift. Because of your stupidity and irrationality, I consistently make money in these beaten down stocks, so thank you again for your gift to me.
Total nonsense. They have 360 days after time notified by Nasdaq. BTW - I just had a stock that I bought after it reverse split that just went up 400% in a little over a month.
Study runs until 2022. They have 180 days plus another 180 days (1 year) to get price up before delisting and can just do a reverse split if needed. This is a steal here at this price with easy 50% upside in a month or two - they now have loads of cash, and Baupost has their back.
This stock should be trading at three times this price or more. The minimum market cap here should be more than $275 Million, not $95 million. I expect this to make a huge run from here. Don't sell! You will kick yourself if you sell.
$.675 is a terrific price - Baupost paid $3 a share and you better believe they researched this way beyond what any short seller did. Also, Baupost has to pay $6 a share when they exercise their warrants. Don't listen to nonsense here.
His last year with the FDA was 2010. (he left Jan 5, 2011). He carries no weight with the FDA now, and he was probably paid by some hedge fund to write that editorial so that they could cover their short position or buy shares (Baupost?) since Contrave sales are now taking off again.
At the very most they will be required to put a piece of paper in with the package that says no heart or cv benefits have yet been determined by the use of Contrave. It will have absolutely no effect on sales because no one is taking Contrave for that reason. I have traded biotechs for years and years and am amazed by how stupid retail investors are, and how easy it is to manipulate them and take their shares. I don't know if it is Baupost buying here or a short hedge fund covering, but it is so obvious that you are being taken advantage of here and stupidly giving up your shares (or shorting) right before the Europe announcement. I've made a ton of money because of you retail dummies who buy way too high on total hype and sell way too low on total nonsense.
I think you are right. I've been a trader since 1987 and Forbes has always been a front for short sellers. They bring out a negative article so shorts can cover just before good news is announced. I've seen it many, many times over the years. That Contract writer article in the LA times is the same. I expect news is coming on European partnership and launch.
They can't pull approval. All the FDA can do is make OREX disclose - a piece of paper with each prescription (cost less than a nickle) explaining that heart and CV benefits have not yet been determined, and no one will read it.
At the most Orex will have to put a piece of paper in with Contrave explaining that the heart benefits have not yet been determined and no one will read it. Cost to OREX about 1-2 cents. Thanks for the shares at an unbelieveable price. European launch announcement and more up front money coming any day now. There is no competition from VVUS or ARNA in Europe because neither of them is approved and generic Phentermine is illegal in Europe. Get ready for this to rocket!
No it doesn't. They get a notice that gives them 180 days to bring stock price above $1. This is so severely underpriced (compare $100 mil market cap to ARNA's $300 mil +) that it will easily go up 50% or more.
You are wrong. You're not counting Takeda milestone payments, Upfront fees as they partner in Europe plus Europe revenues and milestones, Korea revenues and milestones, Rest of World upfront fees and revenues and milestones, revenues increasing in the United States due to increased insurance coverage and less discounting and expanding sales. See my calculation above.
Banks' Surge Takes Europe's Stock Rally Into 2nd Day; HSBC Rises
February 15, 2016 — 12:22 AM PST
Share on FacebookShare on Twitter
Don't Miss Out — Follow Bloomberg On
Facebook Twitter Instagram YouTube
Share on Facebook
Share on Twitter
The optimism that swept through European equities continued as banks headed for their biggest two-day jump since 2011.
Italian lenders and Credit Suisse Group AG led the rally, climbing more than 6 percent after hitting record lows last week. HSBC Holdings Plc rose as it said it will keep its headquarters in the U.K. after considering a relocation to Hong Kong. Europe’s automakers also posted a strong rebound, helped by a weakening euro.
The Stoxx Europe 600 Index climbed 2.5 percent at 8:19 a.m. in London, taking its two-day rebound to 5.5 percent. That would market its biggest jump since 2011 in such a period. U.S. index futures rose. The market is closed for a holiday on Monday.
European equities rallied the most in three weeks on Friday, after hitting their lowest prices since 2013, as banks, miners and energy producers surged at least 5.5 percent. Lenders have been particularly hit in the rout that took $8.4 trillion from global equities this year and the Stoxx 600 down as much as 17 percent. The index reached a valuation of 13.9 times estimated earnings on Friday, down from 17.4 in April, after a gauge tracking volatility expectations climbed to the highest level since August.
Despite the rout, strategists are largely bullish on European equities. They’re projecting a rebound of 23 percent from Friday through the end of the year on signs of an improving economy amid continued European Central Bank stimulus.
Benchmark stock indexes of Italy, Spain and Germany rallied more than 2 percent. Those all lost more than 16 percent this year through Friday, becoming some of the world’s worst performers among 93 equity indexes tracked by Bloomberg.